Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine
about
Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individualsStructural and functional bases for broad-spectrum neutralization of avian and human influenza A virusesH5N1 vaccines in humansInfluenza virus vaccines: lessons from the 2009 H1N1 pandemicPreclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccineHeterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.Clinical vaccine development for H5N1 influenza.Avian influenza pandemic preparedness: developing prepandemic and pandemic vaccines against a moving targetCombination strategies for pandemic influenza response - a systematic review of mathematical modeling studies.Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.A model-based economic analysis of pre-pandemic influenza vaccination cost-effectiveness.AS03B-adjuvanted H5N1 influenza vaccine in children 6 months through 17 years of age: a phase 2/3 randomized, placebo-controlled, observer-blinded trial.Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.Safety of AS03-adjuvanted inactivated split virion A(H1N1)pdm09 and H5N1 influenza virus vaccines administered to adults: pooled analysis of 28 clinical trials.Cross-clade protective immunity of H5N1 influenza vaccines in a mouse model.Development of a vaccine against pandemic influenza viruses: current status and perspectives.AS03-Adjuvanted, Very-Low-Dose Influenza Vaccines Induce Distinctive Immune Responses Compared to Unadjuvanted High-Dose Vaccines in BALB/c Mice.Intranasal vaccination with 1918 influenza virus-like particles protects mice and ferrets from lethal 1918 and H5N1 influenza virus challenge.Current status and progress of prepandemic and pandemic influenza vaccine development.Emulsion-based adjuvants for influenza vaccines.Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.Matrix M H5N1 Vaccine Induces Cross-H5 Clade Humoral Immune Responses in a Randomized Clinical Trial and Provides Protection from Highly Pathogenic Influenza Challenge in Ferrets.Optimal dosing and dynamic distribution of vaccines in an influenza pandemic.A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza virusesPrepandemic H5N1 influenza vaccine adjuvanted with AS03: a review of the pre-clinical and clinical data.Strategies for mitigating an influenza pandemic with pre-pandemic H5N1 vaccines.Economic analysis of pandemic influenza vaccination strategies in Singapore.Persistence of Antibody to Influenza A/H5N1 Vaccine Virus: Impact of AS03 AdjuvantThe economy-wide impact of pandemic influenza on the UK: a computable general equilibrium modelling experiment.Effectiveness and cost-effectiveness of vaccination against pandemic influenza (H1N1) 2009.Effectiveness and cost-effectiveness of expanded antiviral prophylaxis and adjuvanted vaccination strategies for an influenza A (H5N1) pandemicAdvances in novel influenza vaccines: a patent review.Update on antivirals and vaccines for seasonal and potential pandemic use.Antibody Persistence and Booster Responses to Split-Virion H5N1 Avian Influenza Vaccine in Young and Elderly Adults.Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.Pharmaceutical interventions for mitigating an influenza pandemic: modeling the risks and health-economic impacts.Effect on cellular and humoral immune responses of the AS03 adjuvant system in an A/H1N1/2009 influenza virus vaccine administered to adults during two randomized controlled trials.Immunogenicity profile of a 3.75-μg hemagglutinin pandemic rH5N1 split virion AS03A-adjuvanted vaccine in elderly persons: a randomized trial.MF59 adjuvant: the best insurance against influenza strain diversity.
P2860
Q24648051-F864F34E-97BD-4C5A-9EC8-98A882C8B82BQ24649949-E985A713-162F-4FA6-91FC-D21417CD5067Q27000896-34A8721A-C2A7-404A-ADD8-D19FE7077255Q27027029-D203DA2A-D670-40C2-84CA-B980AC7BE87EQ27347652-B3C948CA-FEC5-4C68-82A9-762A63CBBABCQ30209583-BB77F076-F2AE-4E23-B1CD-7697383D1093Q30222083-0F52C477-6C56-4492-ADC9-E6998630E742Q30227194-2F42D579-61FE-4452-B0FC-3A237AA0818AQ30227388-BA44170C-D14C-40DF-9B22-43A547B1B87DQ30360190-D49A5C9B-6D71-457B-B2C4-C65252CA8E95Q30363098-82D02068-33D3-4A72-ABBF-19BD0A96F333Q30367603-D63D5FFB-5C69-423F-A8AD-102BADEB5D07Q30368239-980545F7-28D1-4716-B403-58BA56071EE2Q30369467-48D731CF-6ED4-41D7-AB0A-952BFA335F20Q30372159-FB7C42F5-E10E-4B94-A5E7-46B6C7EDAB0EQ30373784-F31DC567-77F8-407D-AC2C-DE7B4C8C7201Q30374665-ED9967C9-ED0F-4F24-81BE-BDEE105AA0A2Q30375784-0C73F068-7FCC-43F5-88FB-02F66859B902Q30375975-A8DD393E-3575-4484-93B9-4209E91622E8Q30375985-25BAD5B0-F934-400B-8102-F7B894DB61DDQ30375991-FFE5453B-579A-479F-97BF-7B1274C660FDQ30376350-C35E586A-74D0-4EE7-BB31-A48D1294BDC2Q30376523-F9C91551-0764-424B-A21F-75F4B314BBEBQ30377217-CBCFB2FF-85DF-4651-8DE1-9B7326D683B0Q30378421-A8DB0CD0-B337-4622-B25D-42438515CA02Q30380700-B9A2AE05-BA56-490F-9F8C-0AD15001EBB1Q30380974-FDD1574A-56EE-468F-A1BC-7BD66B7EBAA3Q30381280-114CDCCC-8B3A-49FD-8853-AA7899C6CB46Q30382717-49C37025-B70C-4D7C-A5B2-FD3075E017DFQ30383449-55D64557-7DD9-40AA-B06D-F8F711D50911Q30383451-B583DD46-B5F6-4CF8-A727-63B369233D19Q30388514-4F9D33BB-2E53-4DC6-9E28-16C4FB4A29B7Q30389265-429482AD-F963-4DBE-A734-BB221DDF547FQ30394896-E36FC779-FAA8-441C-8D98-2D9A1A213CB5Q30396654-8D9FDD2E-AE54-4735-945F-7162B8C7FBE9Q30396693-B09F12D1-11D3-4A15-9AE7-A75A2F4CE753Q30397016-8D5C57B6-CF53-4DF0-8E8F-0BE0B09E37ADQ30401304-5FF1FF58-5A0C-481D-BDB0-F62B475C757EQ30401306-B6D0BD37-4C67-40E5-805E-79CA13CD8A16Q30402018-D7B5DA33-07B7-49E1-8A8A-FE7E6556C462
P2860
Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine
description
2008 nî lūn-bûn
@nan
2008 թուականին հրատարակուած գիտական յօդուած
@hyw
2008 թվականին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@ast
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en-gb
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@nl
type
label
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@ast
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en-gb
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@nl
altLabel
Broad Clade 2 Cross-Reactive I ...... 5N1 Pandemic Influenza Vaccine
@en
prefLabel
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@ast
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en-gb
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@nl
P2093
P2860
P3181
P1433
P1476
Broad Clade 2 cross-reactive i ...... 5N1 pandemic influenza vaccine
@en
P2093
Emmanuel Hanon
Isabel Leroux-Roels
Mamadou Dramé
Pascal Gérard
Roger Bernhard
P2860
P3181
P356
10.1371/JOURNAL.PONE.0001665
P407
P577
2008-01-01T00:00:00Z